Business Context and Reporting Period
This Form 8-K is filed by BioSig Technologies, Inc. (not Streamex Corp.) on March 6, 2025. The report addresses Item 8.01 (Other Events) concerning the company's compliance with Nasdaq listing requirements following a prior deficiency notice.
Key Financial Metrics and Liquidity
- Recent Capital Raised: The company sold an aggregate of 5,172,321 shares for total consideration of $4,847,497 between January 17, 2025, and March 5, 2025.
- Stockholders' Equity: Management believes the company now holds stockholders' equity of at least $2.5 million as of the filing date.
- Future Financing Capacity: Entered into an Equity Subscription Agreement with Lind Global Fund III, LP, allowing the sale of up to $5.0 million of common stock over the next 36 months.
- Revenue/Profit/Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or debt levels.
Material Changes and Listing Status
The company received a Nasdaq exception on October 18, 2024, to demonstrate compliance with Listing Rule 5550(b) by March 7, 2025. The rule requires either $35 million in market value of listed securities or $2.5 million in stockholders' equity. The recent equity offerings were executed specifically to meet the $2.5 million equity threshold.
Outlook, Risks, and Management Commentary
- Compliance Status: The company awaits formal confirmation from Nasdaq that it has evidenced compliance with the Equity Rule.
- Delisting Risk: If compliant, Nasdaq will continue to monitor the company. If the company fails to evidence compliance in its next periodic report, it may be subject to delisting from the Nasdaq Capital Market.
- Management Action: The company utilized an At-the-Market Offering Agreement with H.C. Wainwright & Co., LLC and a Securities Purchase Agreement with accredited investors to raise necessary capital.
Investor Verification Checklist
- Verify the formal confirmation letter from Nasdaq confirming compliance with the $2.5 million stockholders' equity requirement.
- Confirm the exact closing date and settlement of the $4.85 million in recent share sales.
- Review the terms of the Equity Subscription Agreement with Lind Global Fund III, LP for any restrictive covenants.
- Monitor upcoming periodic reports (10-Q/10-K) to ensure the company maintains the $2.5 million equity threshold to avoid future delisting notices.